Cure8 news brief
This advances a drug candidate (ontunisertib) aimed specifically at fibrostenosing Crohn’s disease — a form of IBD where strictures can block the bowel and endoscopic passability is a meaningful clinical measure.
Progression to a large Phase 2b means the drug’s effects and safety will be tested in a broader population, which could matter to patients seeking non‑surgical options for stricturing disease.
Adults with fibrostenosing Crohn’s disease, patients interested in medical (non-surgical) treatments for strictures, IBD clinicians, and researchers following novel anti-fibrotic or stricture-focused therapies.
Agomab announced the first patient was dosed in NOV-ERA, advancing ontunisertib into a global Phase 2b trial focused on fibrostenosing Crohn’s disease. The trial is randomized, double-blind, placebo-controlled, and will evaluate endoscopic passability at Week 24 as its primary endpoint.
The study will randomize adults to one of three twice-daily dose levels (400 mg, 200 mg, 100 mg) or matching placebo for 52 weeks. Agomab references positive Phase 2a/STENOVA findings and open-label extension safety/tolerability data as rationale for continuing development and for including the 400 mg BID arm.
The article is a company/market-focused press update published on a financial news site; it notes a corporate milestone payment obligation triggered by study initiation but does not provide new efficacy results from NOV-ERA.
This is a corporate press-style report announcing trial initiation and a dosing milestone; it describes trial design and prior Phase 2a/extension support but does not present new efficacy or safety results from NOV-ERA. Endoscopic passability is an objective, procedure-based endpoint (requiring endoscopy) rather than a patient-reported symptom outcome.
The source is a financial news aggregator summarizing a company announcement, so clinical details are limited to what Agomab disclosed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients with fibrostenosing Crohn’s disease face progressive strictures and limited targeted treatments; data from STENOVA’s OLE and the planned NOV‑ERA trial could advance therapies that target both inflammation and...
This report describes open‑label extension data for ontunisertib, an investigational oral drug being tested specifically for fibrostenosing Crohn’s disease.
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
